Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Cellular Oncology
Erschienen in: Cellular Oncology 2/2020

01.11.2019 | Review

HMGB1: an overview of its versatile roles in the pathogenesis of colorectal cancer

verfasst von: Kim Jun Cheng, Mohammed Abdullah Alshawsh, Elsa Haniffah Mejia Mohamed, Surendran Thavagnanam, Ajantha Sinniah, Zaridatul Aini Ibrahim

Erschienen in: Cellular Oncology | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Abstract

Background

In recent years, the high mobility group box-1 (HMGB1) protein, a damage-associated molecular pattern (DAMP) molecule, has been found to play multifunctional roles in the pathogenesis of colorectal cancer. Although much attention has been given to the diagnostic and prognostic values of HMGB1 in colorectal cancer, the exact functional roles of the protein as well as the mechanistic pathways involved have remained poorly defined. This systematic review aims to discuss what is currently known about the roles of HMGB1 in colorectal cancer development, growth and progression, and to highlight critical areas for future investigations. To achieve this, the bibliographic databases Pubmed, Scopus, Web of Science and ScienceDirect were systematically screened for articles from inception till June 2018, which address associations of HMGB1 with colorectal cancer.

Conclusions

HMGB1 plays multiple roles in promoting the pathogenesis of colorectal cancer, despite a few contradicting studies. HMGB1 may differentially regulate disease-related processes, depending on the redox status of the protein in colorectal cancer. Binding of HMGB1 to various protein partners may alter the impact of HMGB1 on disease progression. As HMGB1 is heavily implicated in the pathogenesis of colorectal cancer, it is crucial to further improve our understanding of the functional roles of HMGB1 not only in colorectal cancer, but ultimately in all types of cancers.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
T. Ueda, M. Yoshida, HMGB proteins and transcriptional regulation. Biochim Biophys Acta 1799, 114–118 (2010)CrossRefPubMed
2.
T. Gemoll, J.K. Habermann, S. Becker, S. Szymczak, M.B. Upender, H.P. Bruch, U. Hellman, T. Ried, G. Auer, H. Jornvall, U.J. Roblick, Chromosomal aneuploidy affects the global proteome equilibrium of colorectal cancer cells. Anal Cell Pathol 36, 149–161 (2013)CrossRef
3.
4.
H.X. Yan, H.P. Wu, H.L. Zhang, C. Ashton, C. Tong, H. Wu, Q.J. Qian, H.Y. Wang, Q.L. Ying, p53 promotes inflammation-associated hepatocarcinogenesis by inducing HMGB1 release. J Hepatol 59, 762–768 (2013)CrossRefPubMedPubMedCentral
5.
P. Scaffidi, T. Misteli, M.E. Bianchi, Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature. 418, 191–195 (2002)CrossRefPubMed
6.
C. Janko, M. Filipović, L.E. Munoz, C. Schorn, G. Schett, I. Ivanović-Burmazović, M. Herrmann, Redox modulation of HMGB1-related signaling. Antioxid Redox Signal 20, 1075–1085 (2014)CrossRefPubMedPubMedCentral
7.
E. Venereau, M. Casalgrandi, M. Schiraldi, D.J. Antoine, A. Cattaneo, F. De Marchis, J. Liu, A. Antonelli, A. Preti, L. Raeli, S.S. Shams, H. Yang, L. Varani, U. Andersson, K.J. Tracey, A. Bachi, M. Uguccioni, M.E. Bianchi, Mutually exclusive redox forms of HMGB1 promote cell recruitment or proinflammatory cytokine release. J Exp Med 209, 1519–1528 (2012)CrossRefPubMedPubMedCentral
8.
D.J. Antoine, H.E. Harris, U. Andersson, K.J. Tracey, M.E. Bianchi, A systematic nomenclature for the redox states of high mobility group box (HMGB) proteins. Mol Med 20, 135–137 (2014)CrossRefPubMedPubMedCentral
9.
J. Terzić, S. Grivennikov, E. Karin, M. Karin, Inflammation and Colon Cancer. Gastroenterology 138, 2101–2114.e2105 (2010)CrossRefPubMed
10.
F. Bray, J. Ferlay, I. Soerjomataram, R.L. Siegel, L.A. Torre, A. Jemal, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68, 394–424 (2018)CrossRefPubMed
11.
M.E. Bianchi, DAMPs, PAMPs and alarmins: All we need to know about danger. J Leukoc Biol 81, 1–5 (2007)CrossRefPubMed
12.
13.
14.
H. Wang, O. Bloom, M. Zhang, J.M. Vishnubhakat, M. Ombrellino, J. Che, A. Frazier, H. Yang, S. Ivanova, L. Borovikova, K.R. Manogue, E. Faist, E. Abraham, J. Andersson, U. Andersson, P.E. Molina, N.N. Abumrad, A. Sama, K.J. Tracey, HMG-1 as a late mediator of endotoxin lethality in mice. Science. 285, 248–251 (1999)CrossRefPubMed
15.
H. Yang, H. Wang, S.S. Chavan, U. Andersson, High mobility group box protein 1 (HMGB1): The prototypical endogenous danger molecule. Mol Med 21(Suppl 1), S6–S12 (2015)CrossRefPubMedPubMedCentral
16.
Z. Li, H. Wang, B. Song, Y. Sun, J. Han, Z. Xu, [Expression of high mobility group box-1 in colorectal cancer and its clinical significance]. Zhonghua Wei Chang Wai Ke Za Zhi. 18, 616–619 (2015)
17.
D. Süren, M. Yıldırım, Ö. Demirpençe, V. Kaya, A.S. Alikanoğlu, N. Bülbüller, M. Yıldız, C. Sezer, The role of high mobility group box 1 (HMGB1) in colorectal cancer. Med Sci Monit 20, 530–537 (2014)CrossRefPubMedPubMedCentral
18.
M. Ueda, Y. Takahashi, Y. Shinden, S. Sakimura, H. Hirata, R. Uchi, Y. Takano, J. Kurashige, T. Iguchi, H. Eguchi, K. Sugimachi, H. Yamamoto, Y. Doki, M. Mori, K. Mimori, Prognostic significance of high mobility group box 1 (HMGB1) expression in patients with colorectal cancer. Anticancer Res 34, 5357–5362 (2014)PubMed
19.
X. Zhang, J. Yu, M. Li, H. Zhu, X. Sun, L. Kong, The association of HMGB1 expression with clinicopathological significance and prognosis in Asian patients with colorectal carcinoma: A meta-analysis and literature review. Onco Targets Ther 9, 4901–4911 (2016)CrossRefPubMedPubMedCentral
20.
H.J. Kang, H. Lee, H.-J. Choi, J.H. Youn, J.-S. Shin, Y.H. Ahn, J.S. Yoo, Y.-K. Paik, H. Kim, Non-histone nuclear factor HMGB1 is phosphorylated and secreted in colon cancers. Lab Investig 89, 948 (2009)CrossRefPubMed
21.
Y.R. Choi, H. Kim, H.J. Kang, N.G. Kim, J.J. Kim, K.S. Park, Y.K. Paik, H.O. Kim, H. Kim, Overexpression of high mobility group box 1 in gastrointestinal stromal tumors with KIT mutation. Cancer Res 63, 2188–2193 (2003)PubMed
22.
K. Völp, M.L. Brezniceanu, S. Bösser, T. Brabletz, T. Kirchner, D. Göttel, S. Joos, M. Zörnig, Increased expression of high mobility group box 1 (HMGB1) is associated with an elevated level of the antiapoptotic c-IAP2 protein in human colon carcinomas. Gut. 55, 234–242 (2006)CrossRefPubMedPubMedCentral
23.
L. Cottone, A. Capobianco, C. Gualteroni, C. Perrotta, M.E. Bianchi, P. Rovere-Querini, A.A. Manfredi, 5-fluorouracil causes leukocytes attraction in the peritoneal cavity by activating autophagy and HMGB1 release in colon carcinoma cells. Int J Cancer 136, 1381–1389 (2015)CrossRefPubMed
24.
S. Maeda, Y. Hikiba, W. Shibata, T. Ohmae, A. Yanai, K. Ogura, S. Yamada, M. Omata, Essential roles of high-mobility group box 1 in the development of murine colitis and colitis-associated cancer. Biochem Biophys Res Commun 360, 394–400 (2007)CrossRefPubMed
25.
T. Aychek, K. Miller, O. Sagi-Assif, O. Levy-Nissenbaum, M. Israeli-Amit, M. Pasmanik-Chor, J. Jacob-Hirsch, N. Amariglio, G. Rechavi, I.P. Witz, E-selectin regulates gene expression in metastatic colorectal carcinoma cells and enhances HMGB1 release. Int J Cancer 123, 1741–1750 (2008)CrossRefPubMed
26.
H. Kuniyasu, Y. Chihara, H. Kondo, Differential effects between amphoterin and advanced glycation end products on colon cancer cells. Int J Cancer 104, 722–727 (2003)CrossRefPubMed
27.
K.S. Chandrasekaran, A. Sathyanarayanan, D. Karunagaran, Downregulation of HMGB1 by miR-34a is sufficient to suppress proliferation, migration and invasion of human cervical and colorectal cancer cells. Tumour Biol 37, 13155–13166 (2016)CrossRefPubMed
28.
L. Zhu, X. Li, Y. Chen, J. Fang, Z. Ge, High-mobility group box 1: A novel inducer of the epithelial-mesenchymal transition in colorectal carcinoma. Cancer Lett 357, 527–534 (2015)CrossRefPubMed
29.
Z. Zhang, M. Wang, L. Zhou, X. Feng, J. Cheng, Y. Yu, Y. Gong, Y. Zhu, C. Li, L. Tian, Q. Huang, Increased HMGB1 and cleaved caspase-3 stimulate the proliferation of tumor cells and are correlated with the poor prognosis in colorectal cancer. J Exp Clin Cancer Res 34, 51 (2015)CrossRefPubMedPubMedCentral
30.
L. Cottone, A. Capobianco, C. Gualteroni, A. Monno, I. Raccagni, S. Valtorta, T. Canu, T. Di Tomaso, A. Lombardo, A. Esposito, R.M. Moresco, A.D. Maschio, L. Naldini, P. Rovere-Querini, M.E. Bianchi, A.A. Manfredi, Leukocytes recruited by tumor-derived HMGB1 sustain peritoneal carcinomatosis. Oncoimmunology. 5, e1122860 (2016)CrossRefPubMedPubMedCentral
31.
X. Chen, X. Liu, B. He, Y. Pan, H. Sun, T. Xu, X. Hu, S. Wang, MiR-216b functions as a tumor suppressor by targeting HMGB1-mediated JAK2/STAT3 signaling way in colorectal cancer. Am J Cancer Res 7, 2051–2069 (2017)PubMedPubMedCentral
32.
S. Sharma, A. Evans, E. Hemers, Mesenchymal-epithelial signalling in tumour microenvironment: Role of high-mobility group box 1. Cell Tissue Res 365, 357–366 (2016)CrossRefPubMedPubMedCentral
33.
L. Zhu, L. Ren, Y. Chen, J. Fang, Z. Ge, X. Li, Redox status of high-mobility group box 1 performs a dual role in angiogenesis of colorectal carcinoma. J Cell Mol Med 19, 2128–2135 (2015)CrossRefPubMedPubMedCentral
34.
Y. Li, J. He, D. Zhong, J. Li, H. Liang, High-mobility group box 1 protein activating nuclear factor-kappaB to upregulate vascular endothelial growth factor C is involved in lymphangiogenesis and lymphatic node metastasis in colon cancer. J Int Med Res 43, 494–505 (2015)CrossRefPubMed
35.
J.R. van Beijnum, R.P. Dings, E. van der Linden, B.M. Zwaans, F.C. Ramaekers, K.H. Mayo, A.W. Griffioen, Gene expression of tumor angiogenesis dissected: Specific targeting of colon cancer angiogenic vasculature. Blood. 108, 2339–2348 (2006)CrossRefPubMed
36.
H. Kikuchi, H. Yagi, H. Hasegawa, Y. Ishii, K. Okabayashi, M. Tsuruta, G. Hoshino, A. Takayanagi, Y. Kitagawa, Therapeutic potential of transgenic mesenchymal stem cells engineered to mediate anti-high mobility group box 1 activity: Targeting of colon cancer. J Surg Res 190, 134–143 (2014)CrossRefPubMed
37.
J.R. van Beijnum, P. Nowak-Sliwinska, E. van den Boezem, P. Hautvast, W.A. Buurman, A.W. Griffioen, Tumor angiogenesis is enforced by autocrine regulation of high-mobility group box 1. Oncogene. 32, 363–374 (2013)CrossRefPubMed
38.
Y. Zheng, G. Zhu, HMGB1 suppresses colon carcinoma cell apoptosis triggered by coculture with dendritic cells via an ER stressassociated autophagy pathway. Mol Med Rep 17, 3123–3132 (2018)PubMed
39.
W. Liu, Z. Zhang, Y. Zhang, X. Chen, S. Guo, Y. Lei, Y. Xu, C. Ji, Z. Bi, K. Wang, HMGB1-mediated autophagy modulates sensitivity of colorectal cancer cells to oxaliplatin via MEK/ERK signaling pathway. Cancer Biol Ther 16, 511–517 (2015)CrossRefPubMedPubMedCentral
40.
Y. Luo, J. Yoneda, H. Ohmori, T. Sasaki, K. Shimbo, S. Eto, Y. Kato, H. Miyano, T. Kobayashi, T. Sasahira, Y. Chihara, H. Kuniyasu, Cancer usurps skeletal muscle as an energy repository. Cancer Res 74, 330–340 (2014)CrossRefPubMed
41.
Z. Wang, X. Wang, J. Li, C. Yang, Z. Xing, R. Chen, F. Xu, HMGB1 knockdown effectively inhibits the progression of rectal cancer by suppressing HMGB1 expression and promoting apoptosis of rectal cancer cells. Mol Med Rep 14, 1026–1032 (2016)CrossRefPubMed
42.
G. Gdynia, S.W. Sauer, J. Kopitz, D. Fuchs, K. Duglova, T. Ruppert, M. Miller, J. Pahl, A. Cerwenka, M. Enders, H. Mairbaurl, M.M. Kaminski, R. Penzel, C. Zhang, J.C. Fuller, R.C. Wade, A. Benner, J. Chang-Claude, H. Brenner, M. Hoffmeister, H. Zentgraf, P. Schirmacher, W. Roth, The HMGB1 protein induces a metabolic type of tumour cell death by blocking aerobic respiration. Nat Commun 7, 10764 (2016)CrossRefPubMedPubMedCentral
43.
C.C. Zhang, G. Gdynia, V. Ehemann, W. Roth, The HMGB1 protein sensitizes colon carcinoma cells to cell death triggered by pro-apoptotic agents. Int J Oncol 46, 667–676 (2015)CrossRefPubMed
44.
K.R. Reed, F. Song, M.A. Young, N. Hassan, D.J. Antoine, N.-P.B. Gemici, A.R. Clarke, J.R. Jenkins, Secreted HMGB1 from Wnt activated intestinal cells is required to maintain a crypt progenitor phenotype. Oncotarget. 7, 51665–51673 (2016)CrossRefPubMedPubMedCentral
45.
Y. Luo, Y. Chihara, K. Fujimoto, T. Sasahira, M. Kuwada, R. Fujiwara, K. Fujii, H. Ohmori, H. Kuniyasu, High mobility group box 1 released from necrotic cells enhances regrowth and metastasis of cancer cells that have survived chemotherapy. Eur J Cancer 49, 741–751 (2013)CrossRefPubMed
46.
Y. Luo, H. Ohmori, K. Fujii, Y. Moriwaka, T. Sasahira, M. Kurihara, N. Tatsumoto, T. Sasaki, Y. Yamashita, H. Kuniyasu, HMGB1 attenuates anti-metastatic defence of the liver in colorectal cancer. Eur J Cancer 46, 791–799 (2010)CrossRefPubMed
47.
A. Kusume, T. Sasahira, Y. Luo, M. Isobe, N. Nakagawa, N. Tatsumoto, K. Fujii, H. Ohmori, H. Kuniyasu, Suppression of dendritic cells by HMGB1 is associated with lymph node metastasis of human colon cancer. Pathobiology. 76, 155–162 (2009)CrossRefPubMed
48.
W. Li, K. Wu, E. Zhao, L. Shi, R. Li, P. Zhang, Y. Yin, X. Shuai, G. Wang, K. Tao, HMGB1 recruits myeloid derived suppressor cells to promote peritoneal dissemination of colon cancer after resection. Biochem Biophys Res Commun 436, 156–161 (2013)CrossRefPubMed
49.
Z. Liu, L.D. Falo Jr., Z. You, Knockdown of HMGB1 in tumor cells attenuates their ability to induce regulatory T cells and uncovers naturally acquired CD8 T cell-dependent antitumor immunity. J Immunol 187, 118–125 (2011)CrossRefPubMed
50.
L. Apetoh, F. Ghiringhelli, A. Tesniere, M. Obeid, C. Ortiz, A. Criollo, G. Mignot, M.C. Maiuri, E. Ullrich, P. Saulnier, H. Yang, S. Amigorena, B. Ryffel, F.J. Barrat, P. Saftig, F. Levi, R. Lidereau, C. Nogues, J.P. Mira, A. Chompret, V. Joulin, F. Clavel-Chapelon, J. Bourhis, F. Andre, S. Delaloge, T. Tursz, G. Kroemer, L. Zitvogel, Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 13, 1050–1059 (2007)CrossRefPubMed
51.
R. Lotfi, G.I. Herzog, R.A. DeMarco, D. Beer-Stolz, J.J. Lee, A. Rubartelli, H. Schrezenmeier, M.T. Lotze, Eosinophils oxidize damage-associated molecular pattern molecules derived from stressed cells. J Immunol 183, 5023–5031 (2009)CrossRefPubMed
52.
B. Frey, C. Stache, Y. Rubner, N. Werthmoller, K. Schulz, R. Sieber, S. Semrau, F. Rodel, R. Fietkau, U.S. Gaipl, Combined treatment of human colorectal tumor cell lines with chemotherapeutic agents and ionizing irradiation can in vitro induce tumor cell death forms with immunogenic potential. J Immunotoxicol 9, 301–313 (2012)CrossRefPubMed
53.
H. Kuniyasu, T. Sasaki, T. Sasahira, H. Ohmori, T. Takahashi, Depletion of tumor-infiltrating macrophages is associated with amphoterin expression in colon cancer. Pathobiology. 71, 129–136 (2004)CrossRefPubMed
54.
H. Kuniyasu, S. Yano, T. Sasaki, T. Sasahira, S. Sone, H. Ohmori, Colon cancer cell-derived high mobility group 1/amphoterin induces growth inhibition and apoptosis in macrophages. Am J Pathol 166, 751–760 (2005)CrossRefPubMedPubMedCentral
55.
H. Kumar, T. Kawai, S. Akira, Pathogen recognition by the innate immune system. Int Rev Immunol 30, 16–34 (2011)CrossRefPubMed
56.
J. Galon, A. Costes, F. Sanchez-Cabo, A. Kirilovsky, B. Mlecnik, C. Lagorce-Pagès, M. Tosolini, M. Camus, A. Berger, P. Wind, F. Zinzindohoué, P. Bruneval, P.-H. Cugnenc, Z. Trajanoski, W.-H. Fridman, F. Pagès, Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 313, 1960–1964 (2006)CrossRefPubMed
57.
D.I. Gabrilovich, Myeloid-derived suppressor cells. Cancer Immunol Res 5, 3–8 (2017)
58.
E. Tartour, H. Pere, B. Maillere, M. Terme, N. Merillon, J. Taieb, F. Sandoval, F. Quintin-Colonna, K. Lacerda, A. Karadimou, C. Badoual, A. Tedgui, W.H. Fridman, S. Oudard, Angiogenesis and immunity: A bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy. Cancer Metastasis Rev 30, 83–95 (2011)CrossRefPubMed
59.
F. Shojaei, X. Wu, X. Qu, M. Kowanetz, L. Yu, M. Tan, Y.G. Meng, N. Ferrara, G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models. Proc Natl Acad Sci U S A 106, 6742–6747 (2009)CrossRefPubMedPubMedCentral
60.
C.A. Corzo, T. Condamine, L. Lu, M.J. Cotter, J.I. Youn, P. Cheng, H.I. Cho, E. Celis, D.G. Quiceno, T. Padhya, T.V. McCaffrey, J.C. McCaffrey, D.I. Gabrilovich, HIF-1alpha regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J Exp Med 207, 2439–2453 (2010)CrossRefPubMedPubMedCentral
61.
V. Kumar, P. Cheng, T. Condamine, S. Mony, L.R. Languino, J.C. McCaffrey, N. Hockstein, M. Guarino, G. Masters, E. Penman, F. Denstman, X. Xu, D.C. Altieri, H. Du, C. Yan, D.I. Gabrilovich, CD45 phosphatase inhibits STAT3 transcription factor activity in myeloid cells and promotes tumor-associated macrophage differentiation. Immunity. 44, 303–315 (2016)CrossRefPubMedPubMedCentral
62.
P. Nilendu, S.C. Sarode, D. Jahagirdar, I. Tandon, S. Patil, G.S. Sarode, J.K. Pal, N.K. Sharma, Mutual concessions and compromises between stromal cells and cancer cells: Driving tumor development and drug resistance. Cell Oncol 41, 353–367 (2018)CrossRef
63.
N. Eiro, L. Gonzalez, A. Martinez-Ordonez, B. Fernandez-Garcia, L.O. Gonzalez, S. Cid, F. Dominguez, R. Perez-Fernandez, F.J. Vizoso, Cancer-associated fibroblasts affect breast cancer cell gene expression, invasion and angiogenesis. Cell Oncol 41, 369–378 (2018)CrossRef
64.
N. Maugeri, L. Campana, M. Gavina, C. Covino, M. De Metrio, C. Panciroli, L. Maiuri, A. Maseri, A. D'Angelo, M.E. Bianchi, P. Rovere-Querini, A.A. Manfredi, Activated platelets present high mobility group box 1 to neutrophils, inducing autophagy and promoting the extrusion of neutrophil extracellular traps. J Thromb Haemost 12, 2074–2088 (2014)CrossRefPubMed
65.
A.I. Valderrama-Treviño, B. Barrera-Mera, J.C. Ceballos-Villalva, E.E. Montalvo-Javé, Hepatic metastasis from colorectal Cancer. Euroasian J Hepatogastroenterol 7, 166–175 (2017)CrossRefPubMedPubMedCentral
66.
C. Rüegg, Leukocytes, inflammation, and angiogenesis in cancer: Fatal attractions. J Leukoc Biol 80, 682–684 (2006)CrossRefPubMed
67.
C.Y. Huang, S.F. Chiang, T.W. Ke, T.W. Chen, Y.C. Lan, Y.S. You, A.C. Shiau, W.T. Chen, K.S.C. Chao, Cytosolic high-mobility group box protein 1 (HMGB1) and/or PD-1+ TILs in the tumor microenvironment may be contributing prognostic biomarkers for patients with locally advanced rectal cancer who have undergone neoadjuvant chemoradiotherapy. Cancer Immunol Immunother 67, 551–562 (2018)CrossRefPubMed
68.
G. van Niekerk, A.M. Engelbrecht, Role of PKM2 in directing the metabolic fate of glucose in cancer: A potential therapeutic target. Cell Oncol 41, 343–351 (2018)CrossRef
69.
X. Zhong, B. Chen, Z. Yang, The role of tumor-associated macrophages in colorectal carcinoma progression. Cell Physiol Biochem 45, 356–365 (2018)CrossRefPubMed
70.
F. Sipos, O. Galamb, Epithelial-to-mesenchymal and mesenchymal-to-epithelial transitions in the colon. World J Gastroenterol 18, 601–608 (2012)CrossRefPubMedPubMedCentral
71.
J.P. Thiery, J.P. Sleeman, Complex networks orchestrate epithelial–mesenchymal transitions. Nat Rev Mol Cell Biol. 7, 131 (2006)CrossRefPubMed
72.
C.A. Duckworth, D. Clyde, D.L. Worthley, T.C. Wang, A. Varro, D.M. Pritchard, Progastrin-induced secretion of insulin-like growth factor 2 from colonic myofibroblasts stimulates colonic epithelial proliferation in mice. Gastroenterology 145, 197–208.e193 (2013)CrossRefPubMed
73.
C. Gialeli, A.D. Theocharis, N.K. Karamanos, Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J 278, 16–27 (2011)CrossRefPubMed
74.
A.W. Griffioen, G. Molema, Angiogenesis: Potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol Rev 52, 237–268 (2000)PubMed
75.
S.A. Stacker, M.E. Baldwin, M.G. Achen, The role of tumor lymphangiogenesis in metastatic spread. FASEB J 16, 922–934 (2002)CrossRefPubMed
76.
J.P. Sleeman, W. Thiele, Tumor metastasis and the lymphatic vasculature. Int J Cancer 125, 2747–2756 (2009)CrossRefPubMed
77.
K. Akagi, Y. Ikeda, M. Miyazaki, T. Abe, J. Kinoshita, Y. Maehara, K. Sugimachi, Vascular endothelial growth factor-C (VEGF-C) expression in human colorectal cancer tissues. Br J Cancer 83, 887–891 (2000)CrossRefPubMedPubMedCentral
78.
79.
R.C. Taylor, S.P. Cullen, S.J. Martin, Apoptosis: Controlled demolition at the cellular level. Nat Rev Mol Cell Biol 9, 231 (2008)CrossRefPubMed
80.
81.
O.J. Sansom, K.R. Reed, A.J. Hayes, H. Ireland, H. Brinkmann, I.P. Newton, E. Batlle, P. Simon-Assmann, H. Clevers, I.S. Nathke, A.R. Clarke, D.J. Winton, Loss of Apc in vivo immediately perturbs Wnt signaling, differentiation, and migration. Genes Dev 18, 1385–1390 (2004)CrossRefPubMedPubMedCentral
82.
H. Lee, N. Shin, M. Song, U.B. Kang, J. Yeom, C. Lee, Y.H. Ahn, J.S. Yoo, Y.K. Paik, H. Kim, Analysis of nuclear high mobility group box 1 (HMGB1)-binding proteins in colon cancer cells: Clustering with proteins involved in secretion and extranuclear function. J Proteome Res 9, 4661–4670 (2010)CrossRefPubMed
83.
J. Yun, G. Jiang, Y. Wang, T. Xiao, Y. Zhao, D. Sun, H.J. Kaplan, H. Shao, The HMGB1-CXCL12 complex promotes inflammatory cell infiltration in Uveitogenic T cell-induced chronic experimental autoimmune uveitis. Front Immunol 8, 142 (2017)CrossRefPubMedPubMedCentral
84.
M. Fukumoto, S. Kurisu, T. Yamada, T. Takenawa, α-Actinin-4 Enhances Colorectal Cancer Cell Invasion by Suppressing Focal Adhesion Maturation. PLoS One 10, e0120616 (2015)CrossRefPubMedPubMedCentral
85.
Y. Hayashida, K. Honda, M. Idogawa, Y. Ino, M. Ono, A. Tsuchida, T. Aoki, S. Hirohashi, T. Yamada, E-cadherin regulates the association between beta-catenin and actinin-4. Cancer Res 65, 8836–8845 (2005)CrossRefPubMed
86.
M.R. Rocha, P. Barcellos-de-Souza, A.C.M. Sousa-Squiavinato, P.V. Fernandes, I.M. de Oliveira, M. Boroni, J.A. Morgado-Diaz, Annexin A2 overexpression associates with colorectal cancer invasiveness and TGF-ß induced epithelial mesenchymal transition via Src/ANXA2/STAT3. Sci Rep 8, 11285 (2018)CrossRefPubMedPubMedCentral
87.
R. Seth, J. Keeley, G. Abu-Ali, S. Crook, D. Jackson, M. Ilyas, The putative tumour modifier gene ATP5A1 is not mutated in human colorectal cancer cell lines but expression levels correlate with TP53 mutations and chromosomal instability. J Clin Pathol 62, 598–603 (2009)CrossRefPubMed
88.
H. Aggelou, P. Chadla, S. Nikou, S. Karteri, I. Maroulis, H.P. Kalofonos, H. Papadaki, V. Bravou, LIMK/cofilin pathway and slingshot are implicated in human colorectal cancer progression and chemoresistance. Virchows Arch 472, 727–737 (2018)CrossRefPubMed
89.
S. Shin, K.L. Rossow, J.P. Grande, R. Janknecht, Involvement of RNA helicases p68 and p72 in colon cancer. Cancer Res 67, 7572–7578 (2007)CrossRefPubMed
90.
Y. Sun, M. Luo, G. Chang, W. Ren, K. Wu, X. Li, J. Shen, X. Zhao, Y. Hu, Phosphorylation of Ser6 in hnRNPA1 by S6K2 regulates glucose metabolism and cell growth in colorectal cancer. Oncol Lett 14, 7323–7331 (2017)PubMedPubMedCentral
91.
X. Luo, J. Yao, P. Nie, Z. Yang, H. Feng, P. Chen, X. Shi, Z. Zou, FOXM1 promotes invasion and migration of colorectal cancer cells partially dependent on HSPA5 transactivation. Oncotarget. 7, 26480–26495 (2016)PubMedPubMedCentral
92.
Q. Liao, R. Li, R. Zhou, Z. Pan, L. Xu, Y. Ding, L. Zhao, LIM kinase 1 interacts with myosin-9 and alpha-actinin-4 and promotes colorectal cancer progression. Br J Cancer 117, 563–571 (2017)CrossRefPubMedPubMedCentral
93.
X. Wang, H. Yu, W. Sun, J. Kong, L. Zhang, J. Tang, J. Wang, E. Xu, M. Lai, H. Zhang, The long non-coding RNA CYTOR drives colorectal cancer progression by interacting with NCL and Sam68. Mol Cancer 17, 110 (2018)CrossRefPubMedPubMedCentral
94.
H.X. Li, X.Y. Sun, S.M. Yang, Q. Wang, Z.Y. Wang, Peroxiredoxin 1 promoted tumor metastasis and angiogenesis in colorectal cancer. Pathol Res Pract 214, 655–660 (2018)CrossRefPubMed
95.
C. Li, X. Liu, Y. Liu, X. Liu, R. Wang, J. Liao, S. Wu, J. Fan, Z. Peng, B. Li, Z. Wang, Keratin 80 promotes migration and invasion of colorectal carcinoma by interacting with PRKDC via activating the AKT pathway. Cell Death Dis 9, 1009 (2018)CrossRefPubMedPubMedCentral
96.
B. Zhang, S. Dong, R. Zhu, C. Hu, J. Hou, Y. Li, Q. Zhao, X. Shao, Q. Bu, H. Li, Y. Wu, X. Cen, Y. Zhao, Targeting protein arginine methyltransferase 5 inhibits colorectal cancer growth by decreasing arginine methylation of eIF4E and FGFR3. Oncotarget. 6, 22799–22811 (2015)PubMedPubMedCentral
97.
J. Chen, Y. Wei, Q. Feng, L. Ren, G. He, W. Chang, D. Zhu, T. Yi, Q. Lin, W. Tang, J. Xu, X. Qin, Ribosomal protein S15A promotes malignant transformation and predicts poor outcome in colorectal cancer through misregulation of p53 signaling pathway. Int J Oncol 48, 1628–1638 (2016)CrossRefPubMed
98.
Z. Zhang, F. Zheng, Z. Yu, J. Hao, M. Chen, W. Yu, W. Guo, Y. Chen, W. Huang, Z. Duan, W. Deng, XRCC5 cooperates with p300 to promote cyclooxygenase-2 expression and tumor growth in colon cancers. PLoS One 12, e0186900 (2017)CrossRefPubMedPubMedCentral
99.
S. Ebrahimi, S.I. Hashemy, MicroRNA-mediated redox regulation modulates therapy resistance in cancer cells: Clinical perspectives. Cell Oncol 42, 131–141 (2019)CrossRef
100.
101.
Z.A. Ibrahim, C.L. Armour, S. Phipps, M.B. Sukkar, RAGE and TLRs: Relatives, friends or neighbours? Mol Immunol 56, 739–744 (2013)CrossRefPubMed
102.
H. Yang, M. Ochani, J. Li, X. Qiang, M. Tanovic, H.E. Harris, S.M. Susarla, L. Ulloa, H. Wang, R. DiRaimo, C.J. Czura, H. Wang, J. Roth, H.S. Warren, M.P. Fink, M.J. Fenton, U. Andersson, K.J. Tracey, Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc Natl Acad Sci U S A 101, 296–301 (2004)CrossRefPubMed
103.
J. Li, R. Kokkola, S. Tabibzadeh, R. Yang, M. Ochani, X. Qiang, H.E. Harris, C.J. Czura, H. Wang, L. Ulloa, H. Wang, H.S. Warren, L.L. Moldawer, M.P. Fink, U. Andersson, K.J. Tracey, H. Yang, Structural basis for the proinflammatory cytokine activity of high mobility group box 1. Mol Med 9, 37–45 (2003)CrossRefPubMedPubMedCentral
104.
E. Cerami, J. Gao, U. Dogrusoz, B.E. Gross, S.O. Sumer, B.A. Aksoy, A. Jacobsen, C.J. Byrne, M.L. Heuer, E. Larsson, Y. Antipin, B. Reva, A.P. Goldberg, C. Sander, N. Schultz, The cBio Cancer genomics portal: An open platform for exploring multidimensional Cancer genomics data. Cancer Discov 2, 401–404 (2012)CrossRefPubMed
105.
J. Gao, B.A. Aksoy, U. Dogrusoz, G. Dresdner, B. Gross, S.O. Sumer, Y. Sun, A. Jacobsen, R. Sinha, E. Larsson, E. Cerami, C. Sander, N. Schultz, Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal Sci Signal (2013). https://​doi.​org/​10.​1126/​scisignal.​2004088
Metadaten
Titel
HMGB1: an overview of its versatile roles in the pathogenesis of colorectal cancer
verfasst von
Kim Jun Cheng
Mohammed Abdullah Alshawsh
Elsa Haniffah Mejia Mohamed
Surendran Thavagnanam
Ajantha Sinniah
Zaridatul Aini Ibrahim
Publikationsdatum
01.11.2019
Verlag
Springer Netherlands
Erschienen in
Cellular Oncology / Ausgabe 2/2020
Print ISSN: 2211-3428
Elektronische ISSN: 2211-3436
DOI
https://doi.org/10.1007/s13402-019-00477-5

Weitere Artikel der Ausgabe 2/2020

Cellular Oncology 2/2020 Zur Ausgabe

Original paper

CD147 augmented monocarboxylate transporter-1/4 expression through modulation of the Akt-FoxO3-NF-κB pathway promotes cholangiocarcinoma migration and invasion

Original paper

AR pathway activity correlates with AR expression in a HER2-dependent manner and serves as a better prognostic factor in breast cancer

Original paper

Multiple novel hepatocellular carcinoma signature genes are commonly controlled by the master pluripotency factor OCT4

Original paper

Mechanism of lung adenocarcinoma spine metastasis induced by CXCL17

Original paper

Long non-coding RNA LINC00858 exerts a tumor-promoting role in colon cancer via HNF4α and WNK2 regulation

Review

Tumor dormancy as an alternative step in the development of chemoresistance and metastasis - clinical implications

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Open Access Biomarker Leitthema

Um auch an kleinen Gewebeproben zuverlässige und reproduzierbare Ergebnisse zu gewährleisten ist eine strenge Qualitätskontrolle in jedem Schritt des Arbeitsablaufs erforderlich. Eine nicht ordnungsgemäße Prüfung oder Behandlung des …

Vergleichende Pathologie in der onkologischen Forschung

Pathologie Leitthema

Die vergleichende experimentelle Pathologie („comparative experimental pathology“) ist ein Fachbereich an der Schnittstelle von Human- und Veterinärmedizin. Sie widmet sich der vergleichenden Erforschung von Gemeinsamkeiten und Unterschieden von …

Gastrointestinale Stromatumoren

Open Access GIST CME-Artikel

Gastrointestinale Stromatumoren (GIST) stellen seit über 20 Jahren ein Paradigma für die zielgerichtete Therapie mit Tyrosinkinaseinhibitoren dar. Eine elementare Voraussetzung für eine mögliche neoadjuvante oder adjuvante Behandlung bei …

Personalisierte Medizin in der Onkologie

Zielgerichtete Therapie Leitthema

Aufgrund des erheblichen technologischen Fortschritts in der molekularen und genetischen Diagnostik sowie zunehmender Erkenntnisse über die molekulare Pathogenese von Krankheiten hat in den letzten zwei Jahrzehnten ein grundlegender …